Why Moderna's Stock Is Trading Higher Today

Moderna MRNA is trading higher on Monday.

Reuters reports Moderna has sped up plans for its COVID-19 vaccine and plans late stage human trials in early summer.

Moderna is engaged in creating transformative medicines based on messenger RNA, or mRNA. It transfers the information stored in the genes to the cellular machinery that makes all the proteins required for life. The firm is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases.

Moderna shares were trading up 8% at $64.07 at the time of publication Monday. The stock has a 52-week high of $67.67 and a 52-week low of $11.54.

Related Links:

Volunteers Begin Testing Moderna Coronavirus Vaccine

Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus